Test, treat, and cure.
Test, treat, and cure.
复制标题
测试、治疗和治愈。
DOI：
10.1097/qai.0000000000000385
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Raposo,RuiAndré
中科院分区：
文献类型：
--
作者：
Nixon,DouglasF;Simon,GaryL;Raposo,RuiAndré
由2023年12月4日患者的BhDMf 5ePHKbH 4 TTImqenVA + lpWIIBvonhQl 60 EtgtdlLYrLzSPu + hQedJnbNaXBf下载。[1]密西西比婴儿的潜在第二个病例带来了额外的兴奋;然而，病毒在这个婴儿身上的重新出现使人们对其他功能性治疗的希望暂停。[2]在最近的IAS HIV/AIDS会议上，Zaunders等人3介绍了患者C135，该患者是悉尼血库队列中delta nef缺失的HIV病毒接受者之一，未接受抗逆转录病毒药物治疗，目前无法检测到感染性病毒。这个人是否在功能上治愈或缓解是未知的。C135有一些与疾病进展较慢相关的遗传生物标志物：HLA-B* 57阳性和CCR 5 Delta 32突变的杂合性。作为HIV研究人员制定的策略，旨在向功能性治愈方案，我们建议，在HIV感染者的功能性治愈方案正在考虑中，并在其中治疗性疫苗接种是一个建议的干预措施，免疫基因组学的方法被考虑到优先进行初步研究。例如，具有与缓慢进展相关的HLA或KIR等位基因的那些，例如HLA-B* 57、4 Delta 32 CCR 5杂合性、5内在抗性基因的过表达、6和其他，可以是这些研究的优先候选者。我们称之为“缓解准备”患者的识别。肿瘤学家根据许多生物标志物对患者进行分期，以进入差异化临床实践。艾滋病毒卫生从业人员招募受试者进入功能性治愈方案，包括治疗性免疫接种，应考虑考虑到免疫基因组学时，确定缓解准备患者。虽然艾滋病毒研究的最终目标是一种通用的治愈方法和有效的疫苗，但悉尼血库队列研究表明，遗传学是病毒抑制和潜在缓解的有力指标。免疫基因组学分析可以帮助识别其他这样的“缓解准备患者”。这种策略可以被描述为“测试”（免疫基因组分析）、“治疗”（提供抗逆转录病毒治疗）和“治愈”（为功能性治愈而设计的增强疗法）。
Downloaded from by BhDMf5ePHKbH4TTImqenVA+ lpWIIBvonhQl60EtgtdlLYrLzSPu+ hQedJnbNaXBf on 12/04/2023 patient. 1 The potential second case of the Mississippi baby brought additional excitement; however, the re‐emergence of virus in this infant has given pause to hopes for additional functional cures. 2 At the recent IAS conference on HIV/AIDS, Zaunders et al3 presented on patient C135, one of the delta nef deleted HIV virus recipients in the Sydney blood bank cohort, who is not on antiretroviral medications and in whom infectious virus cannot now be detected. Whether this person is functionally cured or in remission is unknown. C135 has some genetic biomarkers that are associated with slower disease progression: HLA‐B* 57 positivity and heterozygosity for the CCR5Delta 32 mutation. As HIV researchers develop strategies for regimens designed toward functional cure, we propose that in HIV-infected persons in whom functional cure regimens are being considered, and in whom therapeutic vaccination is a proposed intervention, immunogenomic approaches are taken into account to prioritize initial studies. For example, those with HLA or KIR alleles associated with slow progression, such as HLA‐B* 57, 4 Delta 32CCR5 heterozygosity, 5 overexpression of intrinsic resistance genes, 6 and others, could be candidates prioritized for these studies. We call this identification of “remission ready” patients. Oncologists stage patients based on a number of biomarkers for entry into differential clinical practices. HIV health practitioners enrolling subjects into functional cure regimens that include therapeutic immunizations should consider taking immunogenomics into account when identifying remission ready patients. Although the ultimate goal for HIV research is a universal cure and effective vaccine, this Sydney blood bank cohort subject has shown that genetics is a powerful indicator of viral suppression and potential remission. Immunogenomic profiling can help identify other such “remission ready patients.” This strategy could be described as “test”(immunogenomic profiling),“treat”(provide antiretroviral therapy), and “cure”(augmentative therapies designed for functional cures).